Updated on 7 March 2014
However, Adenuga says that lax intellectual property (IP) protection and regulatory compliance in the APAC countries could slow down this boom in investment. Pharmaceutical giants, such as Bayer and Novartis, have recently been hurt by India's weak IP laws.
"Investors are well aware of this situation, but they are in the risk-versus-return business. Ultimately, they have to decide whether trading reimbursement and other challenges they currently face in developed markets are risks they wish to take in the APAC region," Adenuga concludes.